Biotia has announced a joint development agreement with Mayo Clinic to propel precision medicine in infectious disease diagnostics.
The new collaboration seeks to combine Mayo Clinic's clinical expertise and diagnostics with Biotia's innovative microbial analytics platform to enhance patient care through faster, more accurate, and comprehensive infectious disease diagnostic solutions.
Together, Biotia and Mayo Clinic will aim to address one of the most pressing challenges in modern healthcare: timely and precise identification of infectious pathogens. With the rise of global pandemics, antimicrobial resistance, and emerging pathogens, healthcare systems worldwide are increasingly dependent on advanced diagnostic tools to guide clinical decisions.
Biotia's cutting-edge AI-powered sequence analysis capabilities will be used to identify and characterise pathogens isolated from clinical specimens, providing laboratories and clinicians with detailed strain level pathogen identities and actionable information. Mayo Clinic will contribute its expertise in microbial diagnostics, clinical application, data interpretation, and patient care to ensure the solutions are optimised for real-world clinical use.
Biotia's platform integrates next-generation sequencing with a curated pathogen database and advanced bioinformatics, delivering rapid and reliable results that empower clinicians to make informed treatment decisions.
The collaboration is expected to yield new diagnostic solutions that will be piloted at Mayo Clinic, with the potential for broader deployment across healthcare systems worldwide.